Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech
Immunosuppressed kidney transplant (KT) recipients produce a weaker response to COVID-19 vaccination than immunocompetent individuals. We tested antiviral IgG response in 99 KT recipients and 66 healthy volunteers who were vaccinated with mRNA-1273 Moderna or BNT162b2 Pfizer-BioNTech vaccines. A sub...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/1/91 |
| _version_ | 1827369291348967424 |
|---|---|
| author | Dulat Bekbolsynov Andrew Waack Camryn Buskey Shalmali Bhadkamkar Keegan Rengel Winnifer Petersen Mary Lee Brown Tanaya Sparkle Dinkar Kaw Fayeq Jeelani Syed Saurabh Chattopadhyay Ritu Chakravarti Sadik Khuder Beata Mierzejewska Michael Rees Stanislaw Stepkowski |
| author_facet | Dulat Bekbolsynov Andrew Waack Camryn Buskey Shalmali Bhadkamkar Keegan Rengel Winnifer Petersen Mary Lee Brown Tanaya Sparkle Dinkar Kaw Fayeq Jeelani Syed Saurabh Chattopadhyay Ritu Chakravarti Sadik Khuder Beata Mierzejewska Michael Rees Stanislaw Stepkowski |
| author_sort | Dulat Bekbolsynov |
| collection | DOAJ |
| description | Immunosuppressed kidney transplant (KT) recipients produce a weaker response to COVID-19 vaccination than immunocompetent individuals. We tested antiviral IgG response in 99 KT recipients and 66 healthy volunteers who were vaccinated with mRNA-1273 Moderna or BNT162b2 Pfizer-BioNTech vaccines. A subgroup of participants had their peripheral blood leukocytes (PBLs) evaluated for the frequency of T helper 1 (Th1) cells producing IL-2, IFN-γ and/or TNF-α, and IL-10-producing T-regulatory 1 (Tr) cells. Among KT recipients, 45.8% had anti-SARS-CoV-2 IgG compared to 74.1% of healthy volunteers (<i>p</i> = 0.009); also, anti-viral IgG levels were lower in recipients than in volunteers (<i>p</i> = 0.001). In terms of non-responders (≤2000 U/mL IgG), Moderna’s group had 10.8% and Pfizer-BioNTech’s group had 34.3% of non-responders at 6 months (<i>p</i> = 0.023); similarly, 15.7% and 31.3% were non-responders in Moderna and Pfizer-BioNTech groups at 12 months, respectively (<i>p</i> = 0.067). There were no non-responders among controls. Healthy volunteers had higher Th1 levels than KT recipients, while Moderna produced a higher Th1 response than Pfizer-BioNTech. In contrast, the Pfizer-BioNTech vaccine induced a higher Tr1 response than the Moderna vaccine (<i>p</i> < 0.05); overall, IgG levels correlated with Th1(fT<sub>TNF-α</sub>)/Tr1(fT<sub>IL-10</sub>) ratios. We propose that the higher number of non-responders in the Pfizer-BioNTech group than the Moderna group was caused by a more potent activity of regulatory Tr1 cells in KT recipients vaccinated with the Pfizer-BioNTech vaccine. |
| first_indexed | 2024-03-08T09:45:02Z |
| format | Article |
| id | doaj.art-d1c7dbe44b1a4111a68f1e7bbd78df71 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-08T09:45:02Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-d1c7dbe44b1a4111a68f1e7bbd78df712024-01-29T14:26:02ZengMDPI AGVaccines2076-393X2024-01-011219110.3390/vaccines12010091Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTechDulat Bekbolsynov0Andrew Waack1Camryn Buskey2Shalmali Bhadkamkar3Keegan Rengel4Winnifer Petersen5Mary Lee Brown6Tanaya Sparkle7Dinkar Kaw8Fayeq Jeelani Syed9Saurabh Chattopadhyay10Ritu Chakravarti11Sadik Khuder12Beata Mierzejewska13Michael Rees14Stanislaw Stepkowski15Department of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USADepartment of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USADepartment of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USADepartment of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USADepartment of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USADepartment of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USADepartment of Urology, University of Toledo, Toledo, OH 43614, USADepartment of Anesthesiology, University of Toledo, Toledo, OH 43614, USADepartment of Internal Medicine, University of Toledo, Toledo, OH 43614, USADepartment of Electrical Engineering and Computer Science, University of Toledo, Toledo, OH 43614, USADepartment of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USADepartment of Physiology, University of Toledo, Toledo, OH 43614, USADepartment of Internal Medicine, University of Toledo, Toledo, OH 43614, USADepartment of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USADepartment of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USADepartment of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USAImmunosuppressed kidney transplant (KT) recipients produce a weaker response to COVID-19 vaccination than immunocompetent individuals. We tested antiviral IgG response in 99 KT recipients and 66 healthy volunteers who were vaccinated with mRNA-1273 Moderna or BNT162b2 Pfizer-BioNTech vaccines. A subgroup of participants had their peripheral blood leukocytes (PBLs) evaluated for the frequency of T helper 1 (Th1) cells producing IL-2, IFN-γ and/or TNF-α, and IL-10-producing T-regulatory 1 (Tr) cells. Among KT recipients, 45.8% had anti-SARS-CoV-2 IgG compared to 74.1% of healthy volunteers (<i>p</i> = 0.009); also, anti-viral IgG levels were lower in recipients than in volunteers (<i>p</i> = 0.001). In terms of non-responders (≤2000 U/mL IgG), Moderna’s group had 10.8% and Pfizer-BioNTech’s group had 34.3% of non-responders at 6 months (<i>p</i> = 0.023); similarly, 15.7% and 31.3% were non-responders in Moderna and Pfizer-BioNTech groups at 12 months, respectively (<i>p</i> = 0.067). There were no non-responders among controls. Healthy volunteers had higher Th1 levels than KT recipients, while Moderna produced a higher Th1 response than Pfizer-BioNTech. In contrast, the Pfizer-BioNTech vaccine induced a higher Tr1 response than the Moderna vaccine (<i>p</i> < 0.05); overall, IgG levels correlated with Th1(fT<sub>TNF-α</sub>)/Tr1(fT<sub>IL-10</sub>) ratios. We propose that the higher number of non-responders in the Pfizer-BioNTech group than the Moderna group was caused by a more potent activity of regulatory Tr1 cells in KT recipients vaccinated with the Pfizer-BioNTech vaccine.https://www.mdpi.com/2076-393X/12/1/91SARS-CoV-2kidney transplantationmRNA vaccineseropositivityimmunocompromised |
| spellingShingle | Dulat Bekbolsynov Andrew Waack Camryn Buskey Shalmali Bhadkamkar Keegan Rengel Winnifer Petersen Mary Lee Brown Tanaya Sparkle Dinkar Kaw Fayeq Jeelani Syed Saurabh Chattopadhyay Ritu Chakravarti Sadik Khuder Beata Mierzejewska Michael Rees Stanislaw Stepkowski Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech Vaccines SARS-CoV-2 kidney transplantation mRNA vaccine seropositivity immunocompromised |
| title | Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech |
| title_full | Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech |
| title_fullStr | Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech |
| title_full_unstemmed | Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech |
| title_short | Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech |
| title_sort | differences in responses of immunosuppressed kidney transplant patients to moderna mrna 1273 versus pfizer biontech |
| topic | SARS-CoV-2 kidney transplantation mRNA vaccine seropositivity immunocompromised |
| url | https://www.mdpi.com/2076-393X/12/1/91 |
| work_keys_str_mv | AT dulatbekbolsynov differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT andrewwaack differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT camrynbuskey differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT shalmalibhadkamkar differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT keeganrengel differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT winniferpetersen differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT maryleebrown differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT tanayasparkle differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT dinkarkaw differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT fayeqjeelanisyed differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT saurabhchattopadhyay differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT rituchakravarti differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT sadikkhuder differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT beatamierzejewska differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT michaelrees differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech AT stanislawstepkowski differencesinresponsesofimmunosuppressedkidneytransplantpatientstomodernamrna1273versuspfizerbiontech |